Pharmozyme Inc. specializes in advanced diagnostic technologies, particularly in the realm of quantitative polymerase chain reaction (qPCR) products. Their UTI qPCR Panel, known as PFlexU1, is designed to simplify the testing process for the most prevalent urinary tract infection pathogens in the United States. This technology aims to enhance the accuracy and efficiency of UTI diagnostics, making it easier for healthcare providers to identify and treat infections promptly.

In addition to UTI diagnostics, Pharmozyme offers respiratory pathogen panels, specifically PFlex R1 and PFlex R2, which provide flexibility in testing for various respiratory viruses, including COVID-19, RSV, and influenza strains. These panels allow for simultaneous detection of multiple pathogens, catering to the needs of a rapidly evolving healthcare landscape. Furthermore, their Extraction Free COVID-19 RT-PCR Kit is engineered for quick and accurate testing, addressing the urgent demand for reliable COVID-19 diagnostics in a fast-paced environment. Overall, Pharmozyme's technologies are focused on improving diagnostic accuracy and efficiency across multiple infectious diseases.

United States

Disrupting research enzyme/protein production, we are the first to introduce a Taq Polymerase free from background DNA contamination. 
We are now proud to introduce our new RNA extraction free EF1 SARS-CoV-2 Detection Kit, CE marked for in vitro diagnostics! Find out how we plan to have the gold standard of testing available with results in less time it takes to explain your job to grandma!

Pharmozyme Inc

Company Details